Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) was the recipient of a significant drop in short interest in November. As of November 15th, there was short interest totalling 537,900 shares, a drop of 95.4% from the October 31st total of 11,790,000 shares. Based on an average daily volume of 189,500 shares, the days-to-cover ratio is currently 2.8 days. Approximately 7.5% of the company’s shares are sold short.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CTXR. Armistice Capital LLC bought a new stake in Citius Pharmaceuticals in the 2nd quarter valued at about $5,928,000. Vanguard Group Inc. increased its holdings in shares of Citius Pharmaceuticals by 1.5% during the first quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock valued at $6,286,000 after acquiring an additional 104,889 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Citius Pharmaceuticals by 14.1% during the third quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock worth $941,000 after purchasing an additional 232,656 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Citius Pharmaceuticals in the 2nd quarter worth $118,000. Finally, Wealth Advisory Solutions LLC lifted its holdings in shares of Citius Pharmaceuticals by 33.1% in the 3rd quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock worth $101,000 after purchasing an additional 50,000 shares in the last quarter. Institutional investors and hedge funds own 16.88% of the company’s stock.

Citius Pharmaceuticals Trading Down 13.3 %

CTXR stock traded down $0.55 during mid-day trading on Wednesday, reaching $3.60. The company’s stock had a trading volume of 416,582 shares, compared to its average volume of 100,311. Citius Pharmaceuticals has a 12 month low of $2.55 and a 12 month high of $26.75. The business’s 50 day moving average price is $9.35 and its 200 day moving average price is $14.20. The company has a market cap of $650.61 million, a price-to-earnings ratio of -15.00 and a beta of 1.66.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. D. Boral Capital reaffirmed a “hold” rating on shares of Citius Pharmaceuticals in a research note on Friday, November 22nd. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Citius Pharmaceuticals in a research report on Tuesday, November 12th.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.